Completed PHASE2 INTERVENTIONAL NCT00054886

Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer

Phase II Study Of Single-Agent SU011248 In The Second-Line Treatment Of Patients With Metastatic Renal Cell Carcinoma

Sponsor: Pfizer

Interventions SU-011,248

Updated 5 times since 2017 Last updated: May 4, 2007 Started: Jan 31, 2003 Completion: Aug 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Kidney Neoplasms, this trial is completed. The trial is conducted by Pfizer and has accumulated 5 data snapshots since 2003. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Boston, United States , Henderson, United States , Las Vegas, United States , Los Angeles, United States , Madison, United States , Mission Hills, United States , Monterey Park, United States , New York, United States , Northridge, United States and 2 more locations